Market Research Reports Global Pemetrexed Market Report 2019.docx | Page 2

The Global Pemetrexed Market is segmented on the basis of Product Type, Application, End Use
Industry and Region. On the Basis of Product Type segment, the Pemetrexed Market is sub
segmented into 100mg, 500mg. Based on End Use Industry segment, the Pemetrexed Market is sub
segmented into Pleural Mesothelioma, Non-small Cell Lung Cancer.
Some of the Pemetrexed Manufacturers (Eli Lilly, Abbott Healthcare, Cadila Healthcare) Data,
including: Shipment, Price, Revenue, Gross Profit, Interview Record, Business Distribution etc., these
data help the consumer know about the competitors better. This report also covers all the regions
and countries of the world, which shows a regional development status, including market size,
volume and value, as well as price data. New product launches and continuous technological
innovations are the Pemetrexed strategies adopted by the major players.
Market segment by Regions/Countries, this report covers: North America Country (United States,
Canada), South America, Asia Country (China, Japan, India, Korea), Europe Country (Germany, UK,
France, Italy), Other Country (Middle East, Africa, GCC) this report investigates and analyzes the
production, value, price, market share and growth rate for the top manufacturers, Pemetrexed data
from 2019 to 2023.
Pemetrexed Questions Answered in this Report:
1. What will the Pemetrexed Market size be in 2023?
2. What are the Key factors driving the Global Pemetrexed Market?
3. What are the challenges to market growth?
4. Who are the Key players in the Global Pemetrexed Market?
5. What are the market opportunities and threats faced by the Pemetrexed players?
Latest Industry Updates:
Abbott:- A leader in nutrition science research and development, has announced increased access to
Abbott's nutrition metabolic formulas (ANMF) to help infants diagnosed with Inborn Errors of
Metabolism (IEM) in India. The announcement comes on the back of easing of import regulations by
the country’s regulatory authority – FSSAI (Food Safety and Standards Authority of India) under the
Diet4Life initiative, which has made the movement of these critical medical foods simpler and faster
into the country since November 2016. The final approval on IEM products came in June 2017.India
has one of the world’s highest birth rates. Of the nearly 74000 babies born every day, 74 will be
born with IEM. On a yearly basis, this translates to more than 27,000 infants who need specialised
nutrition and medical attention to be able to stay healthy, and even survive.
Speaking on IEM products availability in India, Pawan Kumar Agarwal CEO, FSSAI, “We are delighted
to bridge the gap between critical patients’ needs and world class nutrition solutions by enabling
easy entry into Indian market. FSSAI understands that treating IEM needs a holistic approach
including neonatal screening, monitoring symptoms before arriving at the right nutrition therapy.
Through our “Diet4Life initiative,” we are not only addressing the access issue, but also creating an
ecosystem of nutritionists and paediatricians to understand IEM better in the Indian context.”